Brokerages forecast that OptiNose Inc (NASDAQ:OPTN) will report $7.74 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for OptiNose’s earnings, with the highest sales estimate coming in at $8.77 million and the lowest estimate coming in at $6.70 million. OptiNose posted sales of $1.27 million in the same quarter last year, which would indicate a positive year over year growth rate of 509.4%. The business is expected to issue its next earnings results on Tuesday, August 13th.

On average, analysts expect that OptiNose will report full year sales of $34.46 million for the current fiscal year, with estimates ranging from $31.20 million to $37.73 million. For the next year, analysts forecast that the business will report sales of $83.12 million, with estimates ranging from $75.90 million to $90.35 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover OptiNose.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%. The business had revenue of $4.48 million during the quarter, compared to analyst estimates of $4.35 million.

OPTN has been the subject of a number of analyst reports. Piper Jaffray Companies set a $29.00 target price on shares of OptiNose and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research raised shares of General Moly from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $27.00 target price on shares of Spero Therapeutics in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $23.30.

OPTN traded up $0.12 during trading on Wednesday, reaching $5.99. 151,787 shares of the company’s stock were exchanged, compared to its average volume of 252,797. The firm has a fifty day moving average of $6.88. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.74 and a current ratio of 6.95. OptiNose has a fifty-two week low of $5.50 and a fifty-two week high of $22.96.

Hedge funds have recently made changes to their positions in the company. Two Sigma Advisers LP bought a new stake in OptiNose in the 4th quarter valued at $135,000. American Century Companies Inc. lifted its position in OptiNose by 19.1% in the 4th quarter. American Century Companies Inc. now owns 242,616 shares of the company’s stock valued at $1,504,000 after acquiring an additional 38,842 shares in the last quarter. JPMorgan Chase & Co. lifted its position in OptiNose by 8.1% in the 1st quarter. JPMorgan Chase & Co. now owns 2,503,969 shares of the company’s stock valued at $25,791,000 after acquiring an additional 187,174 shares in the last quarter. Two Sigma Investments LP bought a new stake in OptiNose in the 4th quarter valued at $646,000. Finally, Stifel Financial Corp bought a new stake in OptiNose in the 4th quarter valued at $63,000. 63.68% of the stock is owned by institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

See Also: QQQ ETF

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.